Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice
Open Access
- 15 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 47 (10), 2358-2371
- https://doi.org/10.1007/s00259-020-04712-2
Abstract
PRELUDE aimed to assess use and effectiveness/safety of lanreotide autogel/depot (LAN) combined with 177Lu-DOTATOC or 177Lu-DOTATATE (LAN–peptide receptor radionuclide therapy [PRRT]) in patients with progressive neuroendocrine tumours (NETs).Keywords
Funding Information
- Ipsen
- ASCO Conquer Cancer Foundation Young Investigator Award
- Christie Charity
This publication has 32 references indexed in Scilit:
- Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial DataEuropean Urology, 2014
- Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II studyBMC Cancer, 2013
- Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic ApproachesClinical Cancer Research, 2013
- Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine CancersJournal of Clinical Oncology, 2011
- 90Y-Edotreotide for Metastatic Carcinoid Refractory to OctreotideJournal of Clinical Oncology, 2010
- Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumoursEndocrine-Related Cancer, 2008
- Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanismsEndocrine-Related Cancer, 2008
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and SurvivalJournal of Clinical Oncology, 2008
- Rationale for the use of somatostatin analogs as antitumor agentsAnnals of Oncology, 2006
- Tumor Cell Proliferation Kinetics and Tumor Growth RateActa Oncologica, 1989